BioSpace News Archive

Travere Therapeutics, Inc. provided regulatory updates for its sparsentan programs in IgA nephropathy and focal segmental glomerulosclerosis, as well as its pegtibatinase program for classical homocystinuria.

Amgen announced that its Board of Directors declared a $1.94 per share dividend for the third quarter of 2022.

Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, reported financial results for the second quarter of 2022 and recent corporate updates.

REGENXBIO Inc. announced financial results for the second quarter ended June 30, 2022, and recent operational highlights.

Berkeley Lights, Inc., a leader in digital cell biology, announced its participation at the Cambridge Healthtech Institute’s 14th Annual Bioprocessing Summit being held from August 15 - 18, 2022, virtually and at the Sheraton Boston in Boston, Massachusetts.

PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2022.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced that Pascal Touchon, President and Chief Executive Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 9:00 a.m. PDT / 12:00 p.m. EDT.

Arcus Biosciences, Inc. (NYSE:RCUS), today reported financial results for the second quarter ended June 30, 2022 and provided a pipeline update on its six clinical-stage molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b), HIF-2a and PD-1 – across multiple common cancers.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2022.

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the European Medicines Agency (EMA) issued a positive opinion on the Company’s application for orphan drug designation for tamibarotene for the treatment of myelodysplastic syndrome (MDS).